India's Supreme Court Wants Drug Margin Caps on Every Medicine

On October 12, 2026, India's Supreme Court told the Union government that Drug Margin Caps limited to anti-cancer drugs are nowhere near enough. Solicitor General Tushar Mehta and Additional Solicitor General Aishwarya Bhati appeared for the Centre and said the government will cap the trade margin on anti-cancer drugs at 30% of the maximum retail price, a move expected to save patients roughly Rs 2,500 crore a year, according to LiveLaw's report on the hearing. The bench of Justices Vikram Nath and Sandeep Mehta was unimpressed, calling the response "hardly anything to be happy about" and remarking that there was "nothing for the benefit of the patients." The judges wanted to know a simple thing: if the government can cap prices for cancer drugs, why can it not bring every medicine under the same regime?

The court's scepticism was fuelled by examples of extreme markups raised in the hearing. The bench flagged a case where a saline drip that cost about Rs 11 was sold to patients for Rs 270. It pointed to an India-made cardiac stent with a price to the retailer of roughly Rs 5,000 being sold at hospitals for more than Rs 25,000, and to another formulation whose price to the stockist stood at Rs 78.29 even as its printed maximum retail price was Rs 2,850, according to The Hindu BusinessLine's report on the hearing. "What is the logic behind allowing them to sell 400 times the actual cost? How can you allow this?" the bench asked during the proceedings.

From cancer drugs to every prescription: how the fight escalated

The confrontation did not start this week. At a hearing on September 29, 2026, the same bench had flagged a case where a cancer drug carrying a printed price near Rs 27,000 was supplied to retailers for only about Rs 2,700, and had criticised corporate hospitals that force patients to buy medicines from their in-house chemists, warning that the common person bears the cost of that system. The bench had then floated the idea of a uniform version of Drug Margin Caps: a rule under which the maximum retail price of any medicine could not exceed the price to the retailer by more than 16%. The Centre returned on October 12, 2026 with a 551-page affidavit laying out the existing price-control framework, plus its decision to cap margins on anti-cancer drugs. The bench acknowledged the move but demanded to know why only cancer drugs were covered, saying the pricing problem the judges described touches virtually every prescription.

Related reading on drug policy and research: Dementia Drug Trial Shows Early Biomarker Promise, New Blood Pressure Drug Shines in Obesity Trial Data, and more from the Health beat.

The government has begun to spell out what the cancer-drug cap will look like. The measure will apply to branded and generic versions of selected anti-cancer medicines, both domestically manufactured and imported, with a list of covered drugs to be notified and updated periodically. Inexpensive medicines would be excluded, on the reasoning that restricting margins on cheap products could leave too little room to cover distribution and marketing costs, according to reports on the Centre's proposal.

What it means for young Indians — and what the government says back

For young Indians, this fight is not abstract policy. Students and early-career workers often bear or witness the family's medical bills, and hospital pharmacy charges are one of the most resented parts of that bill. If the court succeeds in pushing the government to extend margin caps across all medicines, the gap between what pharmacies pay and what patients pay could shrink dramatically, cutting out-of-pocket costs for ordinary households at precisely the moment a health emergency strikes.

The government, however, pushed back. Solicitor General Mehta argued that medicine prices cannot be capped beyond a point because higher margins help drugs reach far-flung areas, while ASG Bhati said the cost of medicines in India is among the lowest in the world, a reason patients from other countries travel to India for treatment, according to The Hindu BusinessLine's report on the hearing. Justice Mehta responded that if price-controlled medicines do not reach customers, ensuring supply is the government's duty, and that the real dispute is over which medicines belong on the controlled list in the first place.

The bench has given the Centre until October 27, 2026 to come back with concrete modalities for capping medicine prices, and told the government it would strengthen its hands to act. In its affidavit, the Centre also described the existing framework: the national list of essential medicines, last updated in 2022, covers 388 drugs and more than 900 formulations, with ceiling prices already fixed for hundreds of scheduled formulations, while manufacturers of non-scheduled medicines largely set their own launch prices and are only constrained by a rule limiting annual price hikes. The next hearing will show whether the court turns its uniform-margin suggestion into a directive — and whether the savings the judges are chasing end up in patients' pockets.

For a generation that watches grandparents ration prescriptions and parents crowd-fund surgeries, medicine pricing is a kitchen-table issue — and the October 12, 2026 hearing put it squarely in the spotlight. The court's message was blunt: a system that lets a drug sell at several times its supply price cannot call itself patient-friendly. Whether the government agrees, and what it brings back on October 27, 2026, is the date every young Indian tracking this story should mark.